latest development

News & Events

Jerusalem, Israel, April 4, 2018 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will present an immono-metabolism poster at the AACR Annual Meeting 2018 in Chicago, Illinois. The poster entitled: "A Bi-functional Mechanism of Action: Activating the NLRP3 Inflammasome in Macrophages and Triggering Apoptosis in Cancer Cells via HK2/VDAC Modulator" will be presented as part of the “Immune Response to Therapies 2” session, on Monday Apr 16, 2018 8:00 AM - 12:00 PM. Location: McCormick Place South, Exhibit Hall A, Poster Section 32, Poster Board Number: 20 (Permanent Abstract Number: 1725).

About Vidac Pharma

Vidac is a privately-held clinical-stage oncology and dermatology biopharmaceutical company developing first-in-class drugs. Its breakthrough immuno-metabolic platform technology targets hexokinase 2 (HK2), a metabolic master regulator of proliferation, affecting both cancer and immune cells. Vidac’s drugs modulate HK2-mitochondria binding to trigger selective tumor apoptosis (without affecting the surrounding healthy tissue), reduce immunosuppression, and stimulate anti-tumor immune response. HK2 is over-expressed in a broad range of tumors, especially with tumor-suppression mutations. Vidac’s lead drug, VDA-1102 (ointment), completed Phase 2 POC trial in Actinic Keratosis, an early form of cutaneous SCC, demonstrating safety, tolerability and efficacy. Vidac is also developing systemic treatments for solid tumors and hematological malignancies, as monotherapies and in combinations. For more information please visit

Contact: Shelly Majar +972-2-5952090



pdfDownload PDF

More Press Releases